Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation

Journal of Thoracic Oncology

Volumn 8, Issue 11, 2013, Pages

  Toyokawa, Gouji ^a   Takenoyama, Mitsuhiro ^a   Watanabe, Sawori ^a   Toyozawa, Ryo ^a   Inamasu, Eiko ^a   Kojo, Miyako ^a   Shiraishi, Yoshimasa ^a   Morodomi, Yosuke ^a   Takenaka, Tomoyoshi ^a   Hirai, Fumihiko ^a   Yamaguchi, Masafumi ^a   Taguchi, Kenichi ^a   Seto, Takashi ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; ANAPLASTIC LYMPHOMA KINASE GENE; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE; HUMAN; LUNG ADENOCARCINOMA; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84886470212     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182a008ed     Document Type: Article

References (5)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566
2. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381
3. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019
4. Kaneda H, Okamoto I, Nakagawa K. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J Thorac Oncol 2013;8:e32-e33
5. Ahn HK, Jeon K, Yoo H, et al. Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 2013;8:250-253